Nalaganje...
Alteration in Acute Kidney Injury Potential with the Combination of Vancomycin and Imipenem-Cilastatin/Relebactam or Piperacillin/Tazobactam in a Preclinical Model
The risk of vancomycin (VAN)-associated acute kidney injury (AKI) may be altered with combination regimens. The specific AKI risk when VAN is combined with imipenem-cilastatin/relebactam (IMP-C/REL) or piperacillin/tazobactam (TZP) has not been clearly defined. We sought to quantify the dose-AKI rel...
Shranjeno v:
| izdano v: | Antimicrob Agents Chemother |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Society for Microbiology
2021
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8097411/ https://ncbi.nlm.nih.gov/pubmed/33526494 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02141-20 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|